Bafna Pharmaceuticals Ltd
₹105.11
(-4.44%)
Sat, 14 Mar 2026, 06:33 am
Health Technology
Pharmaceuticals: Major
24.5KBafna Pharmaceuticals Ratios
| Particulars | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings ratio | 0 | 0 | 0 | 24.33 | 24.42 | 20.91 | 45.29 | 17.87 | 22.67 | 8.97 | 0 | 0 | 0 | 0 | 0 | 55.74 | 57.59 | 17.24 | 24.68 | 42.73 |
| Price to book ratio | 0 | 0 | 0 | 0.68 | 1.48 | 1.41 | 1.36 | 1.06 | 0.46 | 0.77 | 0.97 | 1.29 | 1.75 | 1.36 | 0.04 | 5.72 | 4.85 | 2.66 | 2.24 | 2.09 |
| Price to sales ratio | 0 | 0 | 0 | 0.57 | 0.81 | 0.69 | 0.66 | 0.41 | 0.17 | 0.55 | 0.65 | 0.85 | 1.44 | 0.59 | 0.05 | 4.56 | 3.53 | 1.69 | 1.19 | 1.22 |
| Price to cash flow ratio | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.84 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 31.12 | 59.34 | 24.85 | 9.08 |
| Enterprise value | 0 | 0 | 0 | 443.33M | 884.42M | 1.09B | 1.67B | 1.53B | 1.39B | 1.22B | 1.34B | 1.34B | 1.08B | 692.12M | -63.84M | 3.36B | 3.11B | 2.11B | 2.04B | 2.02B |
| Enterprise value to EBITDA ratio | 0 | 0 | 0 | 8.94 | 11.40 | 9.52 | 10.41 | 6.70 | 5.56 | 0 | 107.07 | 0 | 0 | 0 | -4.97 | 32.52 | 25.96 | 13.39 | 18.01 | 17.69 |
| Debt to equity ratio | 2.02 | 0.92 | 1.92 | 0.53 | 0.73 | 0.94 | 1.34 | 1.50 | 1.59 | 0.96 | 1.39 | 1.93 | 1.23 | 2.43 | 0 | 0.23 | 0.18 | 0.31 | 0.30 | 0.33 |
| Return on equity % | 18.58 | 4.75 | 4.79 | 4.24 | 6.24 | 7.03 | 3.12 | 6.04 | 2.06 | 8.78 | -21.66 | -38.01 | -41.53 | -69.77 | -5.37 | 10.80 | 8.79 | 16.63 | 9.52 | 5.01 |
Bafna Pharmaceuticals Ltd Ratios
The Bafna Pharmaceuticals Ltd Ratios page provides a complete fundamental analysis of Bafna Pharmaceuticals Ltd using key valuation, profitability, and financial strength metrics. Investors tracking Bafna Pharmaceuticals Ltd Ratios closely monitor D/E, EV, EV/EBITDA, P/B, P/CF, P/E, P/S, and ROE% to evaluate the company's financial performance and valuation trends over time.
Bafna Pharmaceuticals Ltd (NSE: BAFNAPH, BSE: 532989) is currently trading at ₹105.11, with a market capitalization of ₹2.52B. As a major player in the Health technology sector and Pharmaceuticals: major industry, Bafna Pharmaceuticals Ltd remains a key stock for fundamental analysis using Bafna Pharmaceuticals Ltd Ratios.
Bafna Pharmaceuticals Ltd Ratios: Valuation Overview
Price to Earnings Ratio (P/E)
The Bafna Pharmaceuticals Ltd P/E ratio currently stands at 42.73, making it one of the most tracked metrics in Bafna Pharmaceuticals Ltd Ratios.
Historically, the Bafna Pharmaceuticals Ltd P/E ratio has shown strong fluctuations:
- 2024: 42.73
- 2023: 24.68
- 2022: 17.24
- 2021: 57.59
- 2020: 55.74
The rising Bafna Pharmaceuticals Ltd P/E ratio indicates increasing investor confidence and premium valuation.
Price to Book Ratio (P/B)
The Bafna Pharmaceuticals Ltd P/B ratio reflects how the market values the company's net assets. Current P/B ratio is 2.09.
Historical P/B trend:
- 2024: 2.09
- 2023: 2.24
- 2022: 2.66
- 2021: 4.85
Bafna Pharmaceuticals Ltd shows reasonable valuation compared to its asset base.
Price to Sales Ratio (P/S)
The Bafna Pharmaceuticals Ltd P/S ratio currently stands at 1.22, an important part of Bafna Pharmaceuticals Ltd Ratios for revenue valuation.
Historical P/S ratio:
- 2024: 1.22
- 2023: 1.19
- 2022: 1.69
- 2021: 3.53
The rising Bafna Pharmaceuticals Ltd P/S ratio indicates improved revenue valuation by investors.
Bafna Pharmaceuticals Ltd Price to Cash Flow Ratio (P/CF)
The Bafna Pharmaceuticals Ltd Price to Cash Flow Ratio is a key valuation metric that shows how much investors pay for each unit of cash flow. Current P/CF ratio is 9.08.
Historical Bafna Pharmaceuticals Ltd Price to Cash Flow Ratio:
- 2024: 9.08
- 2023: 24.85
- 2022: 59.34
- 2021: 31.12
- 2020: 0
The declining Bafna Pharmaceuticals Ltd Price to Cash Flow Ratio suggests improving cash flow strength.
Bafna Pharmaceuticals Ltd Enterprise Value Ratios
Enterprise Value (EV)
The Bafna Pharmaceuticals Ltd EV currently stands at ₹2.02B, representing the total company valuation including debt.
Historical EV trend:
- 2024: 2.02B
- 2023: 2.04B
- 2022: 2.11B
- 2021: 3.11B
Bafna Pharmaceuticals Ltd enterprise value consolidation suggests stable valuation.
EV/EBITDA Ratio
The Bafna Pharmaceuticals Ltd EV/EBITDA ratio is currently 17.69, a key metric in Bafna Pharmaceuticals Ltd Ratios to assess valuation relative to earnings.
Historical EV/EBITDA:
- 2024: 17.69
- 2023: 18.01
- 2022: 13.39
- 2021: 25.96
Stable Bafna Pharmaceuticals Ltd EV/EBITDA indicates balanced valuation.
Bafna Pharmaceuticals Ltd Financial Strength Ratios
Debt to Equity Ratio (D/E)
The Bafna Pharmaceuticals Ltd D/E ratio is currently 0.33, reflecting leverage and financial stability.
Historical D/E:
- 2024: 0.33
- 2023: 0.30
- 2022: 0.31
- 2021: 0.18
Bafna Pharmaceuticals Ltd maintains a strong balance sheet with low debt levels.
Return on Equity (ROE %)
The Bafna Pharmaceuticals Ltd ROE currently stands at 5.01%, showing profitability and capital efficiency.
Historical ROE:
- 2024: 5.01
- 2023: 9.52
- 2022: 16.63
- 2021: 8.79
Declining ROE indicates pressure on profitability.
Bafna Pharmaceuticals Ltd Ratios Analysis Summary
The Bafna Pharmaceuticals Ltd Ratios page provides a comprehensive view of the company's valuation and financial performance. Key metrics such as P/E, P/B, P/S, P/CF, EV, EV/EBITDA, D/E, and ROE help investors understand whether Bafna Pharmaceuticals Ltd stock is undervalued, fairly valued, or overvalued.
Tracking Bafna Pharmaceuticals Ltd Ratios regularly helps investors make informed decisions based on valuation trends, financial stability, and long-term growth potential.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800